Helixmith
Helixmith is a Seoul-based private biotechnology company developing cell therapy and regenerative medicine treatments for Critical Limb Ischemia, serving patients with severe peripheral artery disease and high unmet medical need.
- Company typePrivate
- Founded1996
- HeadquartersMapo, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Helixmith does
Helixmith is a privately held biotechnology company founded in 1996 and headquartered in Mapo, Seoul, South Korea, operating with a small team of 11–50 employees. The company is positioned within the regenerative medicine and cell therapy sector, with its primary disclosed focus on treatments for Critical Limb Ischemia (CLI) — a severe form of peripheral artery disease characterized by reduced blood flow, non-healing wounds, and risk of limb amputation. Third-party market research lists Helixmith among the participating companies in the global CLI therapy market alongside larger peers such as Baxter, Hemostemix, Caladrius Biosciences, Vericel Corporation, Ixaka, and Lifecells, in a market estimated at approximately USD 1,845M in 2023 with projected growth through 2034.
The company's therapeutic approach centers on cell-based interventions intended to restore microcirculation, promote tissue regeneration, and prevent amputation in CLI patients. No specific product candidates, clinical trial readouts, technology platform details, regulatory designations, manufacturing footprint, or pricing models are disclosed in the available data. The corporate website currently serves only a security verification page, indicating limited accessible company-level information, and there are no disclosed partners, distributors, or commercial agreements. Founder, CEO, and board member Jong Mook Kim is the only named member of the leadership team in the source material.
The business model cannot be determined from the available data. There is no disclosure of commercial revenue, licensing deals, or capital-raising events, and the firm has no identified customers, payors, or contracted channels. In aggregate, Helixmith presents as a small, founder-led, single-indication clinical-stage biotech with significant information gaps that prevent a more granular assessment of pipeline stage, capitalization, or commercial readiness.
Helixmith firmographics
Firmographics- Name
- Helixmith
- Website
- https://helixmith.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Helixmith is a Seoul-based private biotechnology company developing cell therapy and regenerative medicine treatments for Critical Limb Ischemia, serving patients with severe peripheral artery disease and high unmet medical need.
- Ownership category
- akta.pro rank
Helixmith industry classification
Industry- Product category
- Regenerative Medicine / Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
- akta.pro secondary industries
- Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
Keywords
Where Helixmith is headquartered
LocationHeadquarters
- HQ city
- Mapo
- HQ country
- South Korea
- HQ region
- Asia
Markets served
Helixmith business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Helixmith product offering
Product offeringCore offering
Helixmith is a biotechnology company that develops regenerative medicine and cell/gene therapy treatments, with primary focus on therapies for Critical Limb Ischemia (CLI). The company's products are designed to restore microcirculation, promote tissue regeneration, and prevent limb amputation in patients with severe peripheral artery disease, addressing a clinical area with limited treatment options and high unmet medical need.
Differentiator
Problem solved
Functional benefit
Products and services
- Critical Limb Ischemia Cell Therapy Cell-based regenerative therapy in development to treat Critical Limb Ischemia (CLI), a severe form of peripheral artery disease, aimed at restoring blood flow, promoting tissue regeneration, and preventing limb amputation in patients with high unmet medical need.
Companies that use Helixmith
Customer profileSegments1 record
Ideal customer profiles2 records
Helixmith technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Helixmith partnerships and signals
Strategic signalScale indicators1 record
Expansion highlights1 record
Helixmith competitors and assessment
Company assessmentDirect peers
- Caladrius Biosciences: Clinical-stage cell therapy company developing regenerative medicine treatments, including programs in critical limb ischemia and other ischemic conditions. Directly comparable to Helixmith in modality, indication, and stage of development.
- Vericel Corporation: Commercial-stage cell therapy company focused on autologous cell-based treatments. Comparable in cell therapy modality and regenerative medicine positioning, and explicitly listed alongside Helixmith in the CLI market.
- Hemostemix Inc. Clinical-stage cell therapy company developing regenerative stem cell treatments for critical limb ischemia and other ischemic conditions. Directly comparable indication and modality.
- Ixaka: Cell and gene therapy company developing targeted, multi-cell therapies for serious diseases including ischemic conditions. Listed alongside Helixmith as a key company in the CLI market.
- Lifecells LLC: Company developing cell-based therapies for vascular conditions including critical limb ischemia. Directly listed alongside Helixmith in the CLI market research.
Broad incumbents
- Baxter International: Large global medical products and therapies company with significant presence in vascular and surgical therapies. Listed as a key player in the CLI market and represents a resource-heavy incumbent competitor.
- Mesoblast: Commercial and late-stage cell therapy company with a portfolio of mesenchymal lineage cell therapies for inflammatory and vascular diseases. Comparable modality with broader portfolio reach.
Emerging players
- Pluristem Therapeutics: Cell therapy company developing placenta-derived cell therapies for ischemic and inflammatory conditions including CLI. Comparable in regenerative cell therapy modality with partial indication overlap.
- Athersys: Clinical-stage regenerative medicine company developing MultiStem cell therapy for ischemic and inflammatory indications. Comparable in cell-based regenerative approach to vascular disease.
- Cytori Therapeutics: Cell therapy company developing autologous adipose-derived regenerative cell therapies for ischemic conditions. Modality-comparable peer with overlapping vascular disease focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Helixmith financial estimates
Financial estimateRevenue estimate
Valuation estimate
Helixmith leadership team
Management profileNumber of profiles
Profiles1 record
Helixmith funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Helixmith M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Helixmith
What does Helixmith do?
Helixmith is a biotechnology company that develops regenerative medicine and cell/gene therapy treatments, with primary focus on therapies for Critical Limb Ischemia (CLI). The company's products are designed to restore microcirculation, promote tissue regeneration, and prevent limb amputation in patients with severe peripheral artery disease, addressing a clinical area with limited treatment options and high unmet medical need.
When was Helixmith founded?
Helixmith was founded in 1996. It employs 11 to 50 people.
Where is Helixmith based?
Helixmith is headquartered in Mapo, South Korea, in the Asia region.
Who are Helixmith's main competitors?
Direct peers on record are Caladrius Biosciences, Vericel Corporation, Hemostemix Inc., Ixaka and Lifecells LLC. Broad incumbents are Baxter International and Mesoblast. Emerging players are Pluristem Therapeutics, Athersys and Cytori Therapeutics.
Does Helixmith have an API?
No public API is recorded for Helixmith.
What industry is Helixmith in?
Helixmith's product category is Regenerative Medicine / Cell Therapy. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 325414 and its SIC code is 2836.